Idiopathic Pulmonary Fibrosis - Drug Pipeline Landscape, 2023

Idiopathic Pulmonary Fibrosis - Drug Pipeline Landscape, 2023

Idiopathic pulmonary fibrosis (IPF) is an irreversible, unpredictable, and fatal disease that makes breathing difficult and causes permanent damage to the lungs. With IPF, progressive scarring, or fibrosis of the lungs, prevents muscles, the heart, and other organs from receiving enough oxygen to work properly. IPF typically occurs in people older than 50, affecting slightly more men than women.

Idiopathic pulmonary fibrosis (IPF) can cause scarring in the spaces between the air sacs in the lungs, this makes it more difficult for oxygen to pass into bloodstream. The damage can be caused by many different factors including long-term exposure to certain toxins, certain medical conditions, radiation therapy and some medications.

Signs and symptoms of idiopathic pulmonary fibrosis may include shortness of breath (dyspnea), a dry cough, fatigue, unexplained weight loss, aching muscles, and joints, widening and rounding of the tips of the fingers or toes (clubbing).

Doctors most often diagnose idiopathic pulmonary fibrosis by asking about symptoms. The tests include chest x-ray, high-resolution chest CT, exercise test, biopsy, pulse oximetry and arterial blood gas tests and spirometry.

The most common investigative treatments include two drugs, nintedanib (Ofev) and pirfenidone (Esbriet), oxygen therapy and pulmonary rehabilitation. Symptoms can be eased through lifestyle changes and home remedies like taking healthy food, exercise, quit smoking, get a flu shot and reducing stress.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Idiopathic Pulmonary Fibrosis treatment such as BI 1015550, Pamrevlumab, PRM-151, Treprostinil and others. Key players involved in the development of therapies to treat Idiopathic Pulmonary Fibrosis are FibroGen, Boehringer Ingelheim, Hoffmann-La Roche, United Therapeutics, EmphyCorp Inc and others. One drug is under late-stage pre-registration, four drugs are in Phase III clinical trials and 20+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Idiopathic Pulmonary Fibrosis (IPF) - Drug Pipeline Landscape, 2023 report provides an overview of the Idiopathic Pulmonary Fibrosis (IPF) pipeline drugs. This report covers detailed insights on Idiopathic Pulmonary Fibrosis (IPF) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Idiopathic Pulmonary Fibrosis (IPF) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.